Evaluating a new PET imaging agent for solid tumors
Part of Cancer clinical trials.
This study tests a new imaging agent that lights up certain proteins on solid tumors during a PET scan. It may help doctors better see tumors and guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a solid tumor that is either newly diagnosed or possibly returned after past treatment.
- You must be able to lie still for a PET scan (about 20–30 minutes).
- You must agree to use effective birth control if you or your partner could become pregnant, for 6 months after the test.
- You must be healthy enough to have a life expectancy of more than 6 months.
- You must not have had radioactive drug therapy within a certain time before this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that targets TF-antigen, a molecule found on many solid tumors. The goal is to see if a PET scan can better detect and monitor cancers like lung, breast, or colon cancer.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
This study tests a new type of imaging scan called 68Ga-FAPI-PSMA PET that may help doctors better detect and diagnose solid tumors like prostate, liver, ovarian, or endometrial cancer. You would receive the scan before having a biopsy or surgery.
This study tests whether a new imaging agent called 68Ga-MY6349 can help detect tumors during a PET/CT scan. If you are an adult with a solid tumor (newly diagnosed or already treated), you may be able to take part in this research to see if the new tracer works better than standard imaging.
This study uses a special imaging agent that targets a protein called FAP found on many solid tumors. It helps doctors see tumors more clearly and stage them better. If you have a confirmed solid tumor and are able to undergo PET or SPECT/CT scans, this trial may help improve how your cancer is evaluated.
This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.
Hear when a new PET/CT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.